Who is sponsoring NCT00105534?

NCT00105534 is sponsored by Merck Sharp & Dohme LLC.

What condition does NCT00105534 study?

NCT00105534 studies Bacterial Conjunctivitis.

What drugs are being tested in NCT00105534?

Interventions: AzaSite, Vehicle.

What is the status of NCT00105534?

NCT00105534 is currently COMPLETED.

Last reviewed 2013-10-29 · How we verify

A Study to Evaluate the Clinical and Microbial Efficacy and Safety of 1.0 % AzaSite Compared to Vehicle in the Treatment of Bacterial Conjunctivitis

NCT00105534 Phase 3 COMPLETED Results posted

The purpose of this study is to evaluate the clinical and microbial efficacy and safety of AzaSite compared to vehicle for bacterial conjunctivitis. Adults and children one year of age and older with bacterial conjunctivitis in at least one eye may be eligible. Subjects will be randomly assigned to receive either 1.0 % AzaSite or Vehicle. Three visits will be required for this study.

Details

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 3
Status	COMPLETED
Enrolment	685
Start date	2004-07
Completion	2006-01

Conditions

Bacterial Conjunctivitis

Interventions

AzaSite
Vehicle

Primary outcomes

Participants Who Achieved Clinical Resolution — Visit 3 (Days 6-7)
Clinical Resolution is defined as absence of all three clinical signs: ocular discharge, bulbar conjunctival injection, and palpebral conjunctival injection.

Countries

United States